Vertex Announces Third Quarter 2025 Financial Results and $150 Million Class A Common Stock Repurchase Program

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Vertex Inc.: Vertex Announces Third Quarter 2025 Financial Results and $150 Million Class A Common Stock Repurchase Program

Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...
Investor's Business Daily on MSN

Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book

Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.